ORIGINAL RESEARCH article
Front. Psychiatry
Sec. Social Psychiatry and Psychiatric Rehabilitation
The value of repetitive transcranial magnetic stimulation combined with amisulpride enhancement olanzapine therapy for resistant treatment-refractory schizophrenia
Provisionally accepted
- 1The Third People's Hospital of Yongkang City, Yongkang, China
- 2Zhejiang Provincial Tongde Hospital, Hangzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: Repetitive transcranial magnetic stimulation (rTMS) is a widely used enhancement therapy for schizophrenia, but there are few controlled studies on the combination of rTMS and amisulpride enhancement therapy. The aim of this study is to explore the value of rTMS combined with amisulpride enhanced olanzapine therapy for resistant treatment-refractory schizophrenia (TRS) patients. Methods: We conducted a retrospective analysis based on records of TRS patients who received amisulpride enhanced olanzapine treatment at the Third People's Hospital of Yongkang City from December 2022 to September 2023. Patients are divided into rTMS group and Non-rTMS group based on whether they receive combined rTMS treatment. We examined the patient's Positive and Negative Symptom Rating Scale (PANSS) scores, Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) scores, World Health Organization Quality of Life Questionnaire (WHOQOL-BREF), and incidence of adverse events. Results: After treatment, the scores of PANSS in both groups significantly decreased, and the rTMS group was lower than the Non-rTMS group (P<0.05); The scores of RBANS and WHOQOL-BREF in both groups significantly increased (P<0.05); Except for the attention sub item, all other sub scores in the rTMS group were higher than those in the Non-rTMS group (P<0.05); There was no significant difference in the total number of adverse events between the two groups (P>0.05). Conclusions: The combination of rTMS and amisulpride to enhance olanzapine treatment for TRS may offer potential benefits in symptom management, cognitive function, and quality of life.
Keywords: repetitive transcranial magnetic stimulation, amisulpride enhancement therapy, olanzapine, resistant treatment-refractory, Schizophrenia
Received: 29 Sep 2025; Accepted: 04 Dec 2025.
Copyright: © 2025 Yang, Yu, Li, Zhou and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Qianying Huang
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.